approval. in europe and the uk. and that approval, if it does come, might happen approval, if it does come, might happen next year. but then, a lot more happen next year. but then, a lot more needs happen next year. but then, a lot more needs to happen after that. so, first of more needs to happen after that. so, first of all. more needs to happen after that. so, first of all, let me stress, this is ust first of all, let me stress, this is just for first of all, let me stress, this is just for early stage, people in the early just for early stage, people in the early stages of alzheimer s. but then early stages of alzheimer s. but then there are all kinds of other barriers then there are all kinds of other barriers to then there are all kinds of other barriers to getting this drug. it may barriers to getting this drug. it may cost barriers to getting this drug. it may cost tens of thousands of pounds per year may cost tens of thousands of pounds per year per may c